<u>REMARKS</u>

The specification has been amended so that the title more accurately reflects the claimed subject matter.

Claims 1 and 2 have been canceled without prejudice. New claims 3-37 have been added to more particularly point out and distinctly claim that which Applicants regard as the invention. Support for claims 3-37 can be found in the specification, *inter alia*, at page 3, lines 8-14, page 24, lines 33-36, page 25, lines 14-29, page 42, line 34, and in Section 10, at pages 71-89. No new matter is added.

After entry of the amendments made herein, claims 3-37 will be pending in the present application.

CONCLUSION

Applicants respectfully request entry and consideration of the foregoing amendments and remarks.

		Respectfully submitted,	
Date:	July 10, 2003	Laura A. Coruzzi Laura A. Coruzzi	30,742
	,	Laura A. Coruzzi	(Reg. No.)
		01. 000	
	•	By: // wheel & agam	41,283
		By: Michael J. Ryan	(Reg. No.)

PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, New York 10036-2711 (212) 790-9090

Enclosures

Amendments to the Specification

Please replace the title, at page 1, lines 1-2, with the following rewritten title:

Methods and compositions for poly beta-1-4-N-acetylglucosamine cell therapy system

Biocompatible Poly-β-1→ 4-N-Acetylglucosamine

Please insert the following new paragraph at page 1, line 3:

This is a continuation of application no. 09/866,827 filed May 29, 2001, which is a continuation of application no. 09/227,840, filed January 11, 1999, which is a division of application no. 08/471,290, filed June 6, 1995, now issued as U.S. Patent No. 5,858,350, which is a continuation-in-part of application no. 08/437,911, filed December 1, 1994, now issued as U.S. Patent No. 5,623,064, which is a continuation-in-part of application no. 08/160,569, filed December 1, 1993, now issued as U.S. Patent No. 5,622,834, the entire contents of each of which are incorporated herein by reference in their entirety.